Sign In
Buy GERN
$1.34
+0.0600 (+4.69%)
At Close: Aug 04, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that
Geron Corporation: A High-Risk Deal With A Good Chance Of Success
05:49pm, Thursday, 23'rd May 2024
Geron Corporation's unique product, Imetelstat, could potentially bring real benefits to hematological diseases with a Total Addressable Market value of $7 billion by 2031. Clinical studies have shown
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 16'th May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an a
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
09:21am, Thursday, 02'nd May 2024
Geron (GERN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.07 per share a year ago.
Geron Corporation Reports First Quarter 2024 Financial Results and Business Highlights
07:00am, Thursday, 02'nd May 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to t
The Top 3 Penny Stocks to Buy in April 2024
06:46am, Thursday, 02'nd May 2024
Investing in certain penny stocks to buy during a volatile economy can present unique opportunities for investors. Typically priced below $5 per share (at a discount), these stocks often exhibit heigh
Geron: FDA PDUFA Review With Continued Imetelstat Advancement
04:23pm, Wednesday, 01'st May 2024
Geron Corporation has a PDUFA date of June 16th of 2024 for the FDA to decide upon whether imetelstat should be approved for patients with low-risk myelodysplastic syndrome. The FDA Oncologic Drugs Ad
3 'Buy-Rated' Biotech Stocks Under $10
04:39am, Sunday, 28'th Apr 2024
Today, we look at three small-cap biotech/biopharma stocks. All three have attractive risk/reward profiles and potential catalysts on the horizon. An investment synopsis on all three firms is presente
Geron to Announce First Quarter 2024 Financial Results on May 2, 2024
04:30pm, Thursday, 25'th Apr 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results a
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Thursday, 18'th Apr 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an a
Geron to Participate at Upcoming Investor Conferences in April
04:30pm, Wednesday, 03'rd Apr 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executi
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
06:10am, Wednesday, 20'th Mar 2024
Geron Inc. NASDAQ: GERN is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their lead
Geron Corporation Announces Pricing of $150 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
09:07am, Tuesday, 19'th Mar 2024
FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an underwritten offering consisting of 41,999,99
Choosing the Right Penny Stocks, 3 Hot Tips
05:21am, Monday, 18'th Mar 2024
Navigating the realm of penny stocks can unlock pathways to significant financial growth, presenting a landscape ripe with opportunities for those astute enough to capitalize on them. Central to achie
Can Geron Corporation maintain momentum following FDA's backing?
08:31am, Sunday, 17'th Mar 2024
Friday saw an unprecedented surge in the stock of Geron Corporation (NASDAQ:GERN), with shares ending the day up a staggering 92%. This surge, marking a historic milestone for the company, was ignited
